• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

information for practice

news, new scholarship & more from around the world


advanced search
  • gary.holden@nyu.edu
  • @ Info4Practice
  • Archive
  • About
  • Help
  • Browse Key Journals
  • RSS Feeds

Alzheimer’s drug developers accuse clinical trial sites of faking data

Science | J Ritchie
Science | J Ritchie

This clinical trial site and four others also in the Miami area are being sued by the drug developer T3D Therapeutics…. In its complaint, T3D charged Clinilabs, the contract research organization (CRO) that it paid $14.5 million to manage the trial, with covering up “all encompassing” fraud by five of the South Florida clinics that had recruited many of the subjects, administered the drug, and reported results. The trial sites are all for-profit companies with small offices—or, in one case, a mobile clinic plastered with patient recruitment ads—that specialize in clinical testing rather than routine treatments. T3D alleged they had manipulated data, boosted revenue by enrolling many candidates who did not have Alzheimer’s, and collected payments for screening out others who obviously should never have been considered.

Posted in: News on 01/15/2026 | Link to this post on IFP |
Share

Primary Sidebar

Categories

Category RSS Feeds

  • Calls & Consultations
  • Clinical Trials
  • Funding
  • Grey Literature
  • Guidelines Plus
  • History
  • Infographics
  • Journal Article Abstracts
  • Meta-analyses - Systematic Reviews
  • Monographs & Edited Collections
  • News
  • Open Access Journal Articles
  • Podcasts
  • Video

© 1993-2026 Dr. Gary Holden. All rights reserved.

gary.holden@nyu.edu
@Info4Practice